Although anti-angiogenic therapies with anti-VEGF antibodies and other VEGF inhibitors have been popular, their effect is often transitory, and tumours can regrow with increased aggressiveness following cessation of the treatment2, 3. Here, VEGFA is linked to neoplasm.